诺唯赞(688105)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
西部证券 2024-04-28 增持
东方证券 2024-03-29 买入
中泰证券 2024-02-03 买入
  盈利预测
据诺唯赞四季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力明显恶化,公司规模由扩张变为收缩

  偿债能力维持稳定,财务杠杆风险加大

  运营能力明显恶化,总资产利用效率腰斩

  现金流能力明显恶化,销售回款能力短期内恶化

  财务数据
    截至2024年第一季度实现净利润0.05亿元,每股收益0.01元。

    截至2024年第一季度最新股东权益399770.22万元,未分配利润101383.44万元。

    截至2024年第一季度最新总资产541338.60万元,负债141568.38万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入301,571,120.221,285,988,243.93869,295,118571,036,914.17
营业总成本317,250,391.131,403,136,207.06989,192,793.58666,548,736.19
营业利润-5,804,441.31-100,180,235.37-97,293,987.61-106,828,104.1
利润总额-2,364,812.29-115,714,258.56-108,247,721.97-106,954,270.91
净利润4,875,266.29-72,861,969.23-77,716,085.16-81,988,982.54
其他综合收益-239,321.16-1,719,260.04-3,114,723.21-3,363,548.62
综合收益总额4,635,945.13-74,581,229.27-80,830,808.37-85,352,531.16
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计3,865,117,507.354,230,257,556.924,213,680,674.844,296,072,597.24
非流动资产合计1,548,268,507.181,515,914,981.541,498,458,894.981,459,864,688.54
资产总计5,413,386,014.535,746,172,538.465,712,139,569.825,755,937,285.78
流动负债合计1,180,852,925.061,519,503,632.871,529,353,902.11,549,272,979.32
非流动负债合计234,830,854.88197,388,503.61165,167,948.77189,686,410.06
负债合计1,415,683,779.941,716,892,136.481,694,521,850.871,738,959,389.38
归属于母公司股东权益合计3,998,150,697.364,029,387,759.534,017,146,301.434,016,074,998.31
股东权益合计3,997,702,234.594,029,280,401.984,017,617,718.954,016,977,896.4
负债和股东权益合计5,413,386,014.535,746,172,538.465,712,139,569.825,755,937,285.78
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计274,389,512.381,848,483,633.91,356,086,403.171,051,743,018.58
经营活动现金流出小计355,886,379.671,695,495,665.091,374,681,385.591,006,971,144.16
经营活动产生的现金流量净额-81,496,867.29152,987,968.81-18,594,982.4144,771,874.42
投资活动现金流入小计1,463,552,825.785,338,032,870.743,415,829,373.962,444,995,108.64
投资活动现金流出小计986,492,802.56,238,683,862.344,325,255,206.912,413,792,440.26
投资活动产生的现金流量净额477,060,023.28-900,650,991.6-909,425,832.9531,202,668.38
筹资活动现金流入小计539,500,0001,461,555,352.811,387,800,0001,114,000,000
筹资活动现金流出小计874,238,672.191,211,754,462.21979,526,601.32770,460,908.16
筹资活动产生的现金流量净额-334,738,672.19249,800,890.6408,273,398.68343,539,091.84
汇率变动对现金及现金等价物的影响-160,422.431,462,660.822,519,758.023,071,962.57
现金及现金等价物净增加额60,664,061.37-496,399,471.37-517,227,658.66422,585,597.21
期末现金及现金等价物余额908,855,353.96848,191,292.59827,363,105.31,767,176,361.17
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至2024年第一季度实现净利润0.05亿元,每股收益0.01元。

    截至2024年第一季度最新股东权益399770.22万元,未分配利润101383.44万元。

    截至2024年第一季度最新总资产541338.60万元,负债141568.38万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入301,571,120.221,285,988,243.93869,295,118571,036,914.17
营业总成本317,250,391.131,403,136,207.06989,192,793.58666,548,736.19
营业利润-5,804,441.31-100,180,235.37-97,293,987.61-106,828,104.1
利润总额-2,364,812.29-115,714,258.56-108,247,721.97-106,954,270.91
净利润4,875,266.29-72,861,969.23-77,716,085.16-81,988,982.54
其他综合收益-239,321.16-1,719,260.04-3,114,723.21-3,363,548.62
综合收益总额4,635,945.13-74,581,229.27-80,830,808.37-85,352,531.16
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计3,865,117,507.354,230,257,556.924,213,680,674.844,296,072,597.24
非流动资产合计1,548,268,507.181,515,914,981.541,498,458,894.981,459,864,688.54
资产总计5,413,386,014.535,746,172,538.465,712,139,569.825,755,937,285.78
流动负债合计1,180,852,925.061,519,503,632.871,529,353,902.11,549,272,979.32
非流动负债合计234,830,854.88197,388,503.61165,167,948.77189,686,410.06
负债合计1,415,683,779.941,716,892,136.481,694,521,850.871,738,959,389.38
归属于母公司股东权益合计3,998,150,697.364,029,387,759.534,017,146,301.434,016,074,998.31
股东权益合计3,997,702,234.594,029,280,401.984,017,617,718.954,016,977,896.4
负债和股东权益合计5,413,386,014.535,746,172,538.465,712,139,569.825,755,937,285.78
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计274,389,512.381,848,483,633.91,356,086,403.171,051,743,018.58
经营活动现金流出小计355,886,379.671,695,495,665.091,374,681,385.591,006,971,144.16
经营活动产生的现金流量净额-81,496,867.29152,987,968.81-18,594,982.4144,771,874.42
投资活动现金流入小计1,463,552,825.785,338,032,870.743,415,829,373.962,444,995,108.64
投资活动现金流出小计986,492,802.56,238,683,862.344,325,255,206.912,413,792,440.26
投资活动产生的现金流量净额477,060,023.28-900,650,991.6-909,425,832.9531,202,668.38
筹资活动现金流入小计539,500,0001,461,555,352.811,387,800,0001,114,000,000
筹资活动现金流出小计874,238,672.191,211,754,462.21979,526,601.32770,460,908.16
筹资活动产生的现金流量净额-334,738,672.19249,800,890.6408,273,398.68343,539,091.84
汇率变动对现金及现金等价物的影响-160,422.431,462,660.822,519,758.023,071,962.57
现金及现金等价物净增加额60,664,061.37-496,399,471.37-517,227,658.66422,585,597.21
期末现金及现金等价物余额908,855,353.96848,191,292.59827,363,105.31,767,176,361.17
  十大流通股东
十大流通股东 报告期:2024-03-31
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
国寿成达(上海)健康产业股权投资中心(有限合伙)3095.8018.440.00
杨奇2180.3912.990.00
深圳旦恩先锋投资管理有限公司-深圳旦恩创业投资合伙企业(有限合伙)1412.948.42-64.94
南京诺泰投资合伙企业(有限合伙)1259.337.500.00
珠海广发信德敖东医药产业股权投资中心(有限合伙)788.194.700.00
杨可婧467.692.790.00
中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金334.761.9939.92
贾支俊242.701.450.00
深圳市分享成长投资管理有限公司-深圳市分享精准医疗投资合伙企业(有限合伙)213.751.270.00
香港中央结算有限公司155.120.92155.12
  主力控盘
  公司简介
诺唯赞 所属地域: 江苏省 涉及概念: 阿尔茨海默概念,基因测序,沪股通,抗原检测,新冠检测,融资融券
主营业务: 生物试剂、酶制试剂研发、生产、销售、技术咨询及技术服务;生化试剂及耗材、机电设备、电子产品销售;自营和代理各类商品及技术的进出口业务(国家限定企业经营或禁止进出口商品和技术的除外)。(依法须经批准的项目,经相关部门批准后方可开展经营活动)一般项目:实验分析仪器销售;实验分析仪器制造;机械设备研发;技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广(除依法须经批准的项目外,凭营业执照依法自主开展经营活动)
上市日期: 2021-11-15 每股净资产: 10.00元 每股收益: 0.01元 净利润: 0.05亿元 净利润增长率: 110.30%
营业收入: 3.02亿元 每股现金流: -0.20元 每股公积金: 6.16元 每股未分配利润: 2.53元 总股本: 4.00亿 流通股: 1.68亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心